Abstract
Major depression, a common mental illness affecting millions of people worldwide, is one of the leading causes of morbidity and has a significant economic cost. Although the mechanisms of action are not well understood, antidepressants, including serotonin-selective reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), have been used for the treatment of depression, anxiety and other psychiatric disorders.1 Here we identified a Wnt signaling inhibitor, secreted frizzled-related protein (sFRP3), as a molecular target of antidepressant treatments in rodent models, and revealed the significant association of three single-nucleotide polymorphisms (SNPs) in FRZB (the sFRP3 human ortholog) with early antidepressant responses in a clinical cohort.
Original language | English |
---|---|
Pages (from-to) | 957-958 |
Number of pages | 2 |
Journal | Molecular Psychiatry |
Volume | 18 |
Issue number | 9 |
Early online date | 4 Dec 2012 |
DOIs | |
Publication status | Published - 1 Sept 2013 |